Werewolf Therapeutics’ hunt for strategic alternatives has ended. | Werewolf Therapeutics’ hunt for strategic alternatives ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
As the dust settles on a phase 3 announcement that added $45 billion to Moderna’s market cap, analysts have begun to ask a ...
Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a ...
Lilly pens deal with Gateway Labs resident Amplitude for RNA vaccine platform for infectious disease
Eli Lilly has turned to one of its Gateway Labs residents to help the Big Pharma develop trans-amplifying RNA (taRNA) ...
The FDA has approved Vitestro’s Aletta as the first standalone robotic device in the U.S. designed to draw blood without the need for hands-on human help. | The FDA has approved Vitestro’s Aletta as ...
Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival (RFS) when ...
Capitol Hill lawmakers and the Trump administration have been ramping up the scrutiny of Chinese biotechs as U.S. companies ...
Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your hard-earned ...
After three months without a permanent leader in place, President Donald Trump looks set to name a new commissioner of the ...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...
TScan has told Fierce that its pipeline strategy remains unchanged despite Amgen walking away from a Crohn’s disease ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results